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Sllmmary 
It is generally accepted  that virus-specific  CD8 + cytotoxic T  lymphocytes (CTLs) recognize 
nine-amino acid peptides in conjunction with HLA class I molecules. We recently reported that 
dengue virus-specific CD8 + CTLs of two different serotype specifidties, which were established 
by stimulation with dengue virus, recognize a single nine-amino acid peptide of the nonstruc- 
tural protein NS3 of dengue virus type 4 (D4V) in an HLA-B35-restricted fashion. To further 
analyze the relationships between the serotype specificities ofT cells and the amino acid sequence 
of the recognized peptides,  we examined the ability of this  viral  peptide D4.NS3.500-508 
(TPEGIIFTL) to stimulate T lymphocytes of an HLA-B35-positive, dengue virus type 4-immune 
donor. Peptide stimulation of the PBMC generated dengue virus-specific,  HLA-B35-restricted 
CD8 § CTL clones. These clones lysed dengue virus-infected autologous cells, as well as autol- 
ogous target cells pulsed with this peptide. Four patterns of dengue virus serotype specificities 
were demonstrated on target cells infected with dengue-vaccinia recombinant viruses or pulsed 
with synthetic peptides corresponding to amino acid sequences of four dengue virus serotypes. 
Two serotype-specific clones recognized only D4V. Three dengue virus subcomplex-specific clones 
recognized D1V, D3V, and D4V, and one subcomplex-spedfic clone recognized D2V and D4V. 
Three dengue virus serotype-cross-reactive clones recognized D1V-D4V. Thus, a single nine-amino 
acid peptide induces proliferation of a heterogeneous panel of dengue virus-specific CD8 + CTL 
clones that are all restricted by HLA-B35 but have a variety of serotype specificities. Peptides 
that contain a single amino acid substitution at each position of D4.NS3.500-508 were recog- 
nized differently by the T cell clones. These results indicate that a single epitope can be recog- 
nized by multiple CD8 + CTLs that have a variety of serotype specificities, but the manner of 
recognition by these multiple CTLs is heterogeneous. 
H 
uman  T  lymphocytes recognize  antigenic  peptides 
that are bound to HLA (1, 2). TCRs consist of a het- 
erodimer of oe and 3 chains expressed on the cell surface and 
are responsible for recognition of the peptide--HLA complexes 
(3, 4). The specificity of T lymphocytes is, therefore,  deter- 
mined by the interaction of TCRs with peptide-HLA com- 
plexes. It is generally accepted that the V(D)Jjunction (com- 
plementarity  determining region  [CDR] t  3  portion)  of 
1  Abbreviations used in tkis~r: CD, complimentarity  determining region; 
DHF, dengue hemorrhagic  fever; D1V-D4V, dengue virus types 1-4; LCL, 
B lymphoblastoid cell lines; TCGF, T cell growth factor; VV, vaccinia 
virus; VV-DV, vaccinia dengue recombinant virus. 
TCR is mainly responsible for recognition of peptide, and 
that the CDR1 and CDR2 portions recognize HLA (5); how- 
ever, how the TCR interacts with peptide and HLA is not 
completely understood (6). 
Virus-specific CTLs play an important role in recovery from 
infection (7, 8) and in immunopathological  mechanisms that 
may occur in viral infections (9-11).  Virus-specific CD8 + 
CTLs are heterogeneous in their serotype specificities:  serotype- 
specifc CTLs that recognize one serotype of the virus and 
serotype-cross-reactive  CTLs that recognize more than one 
serotype (12). The peptides that bind to HLA class I mole- 
cules and are recognized by HLA class I-restricted CD8 + 
CD4-  CTLs  are  usually nine-amino acid  peptides  (13). 
853  J. Exp. Med. ￿9  The Rockefeller University Press ￿9 0022-1007/95/09/0853/11  $2.00 
Volume 182  September 1995  853-863 Serotype specificity and  serotype cross-reactivity of virus- 
specific CD8 + CTLs are believed to be determined by the 
degree of conservation of the amino acid sequences among 
serotypes. Thus, it is likely that epitopes that are not con- 
served among serotypes of certain viruses are recognized by 
serotype-specific CTLs,  while epitopes that  are conserved 
among serotypes are recognized by serotype--cross-reactive 
CTLs. Ahhough this may be generally the case, we have re- 
cently described dengue virus-specific CTL clones that have 
different serotype specificities:  dengue virus type 4  (D4V) 
serotype-specific and D4V-D2V cross-reactive, but recog- 
nizing the same nine-amino acid peptide in an HLA-B35-re- 
stricted  fashion  (14).  This  resuh  suggests  that  serotype 
specificity and cross-reactivity may be determined, not only 
by the degree of conservation in the amino acid sequences 
of the epitopes, but also by the T cell itself via its TCR. T  cells 
that possess a very specific TCR are serotype specific, while 
T  cells that possess  a less specific TCR are serotype cross- 
reactive, even though these two groups of T ceils recognize 
the same epitope. 
In this paper, we further elucidate the relationship between 
the  amino  acid  sequences  of a  peptide  and  the  serotype 
specificities  of the T  cells that recognize the peptide. After 
stimulation of PBMC with a single nine-amino acid pep- 
tide, we established virus-specific CTL clones that recognize 
the stimulating peptide with the same HLA restriction but 
have heterogeneous serotype specificities.  These results sug- 
gest that T cell serotype specificities and cross-reactivities may 
not be solely determined by the degree of amino acid conser- 
vations of the epitopes among serotypes. 
Materials  and Methods 
Viruses.  D2V (New Guinea C strain) and D4V, (814669 strain), 
were used in this study. These viruses were propagated in C6/36 
mosquito  cells as previously described (15). Briefly, C6/36 cell 
monolayers were infected at a multiplicity of infection of 0.1 PFU 
per cell and were incubated for 7 d at 28~  in MEM containing 
2% FCS (GIBCO BILL, Gaithersburg; MD) and 0.8% BSA, and 
the supernatant was collected and stored at  -70~  Viral titers 
of the supernatants were 107-10  s PFU/ml by plaque assay on CV-1 
cell monolayers (16). 
The NS3 gene of D2V (New Guinea C strain) and D3V (H-87 
strain) were amplified from appropriate genomic RNAs using re- 
verse transcription PCR with primers that contained BamH1 and 
HindIII restriction sites. The resulting PCR product was ligated 
into the vaccinia transfer plasmid, pKG19, which contains both 
BamH1 and HindIII restriction sites in its cloning cassette. Tram- 
fection of pGK19 vectors into vaccinia virus (VV) strain WR- 
infected CV-1 cells results in recombination at the viral thymidine 
kinase gene locus. VV recombinants that contained the dengue 
NS3 gene were isolated after growth in BudR, confirmed by PCK, 
plaque purified three times, and grown to titers of 0.5-5  x  10  s 
PFU/ml on CV-1 cells. The presence  of  the NS3 gene in VV-infected 
CV-1 cells was demonstrated by SDS-PAGE. An additional VV, 
which contains the NS3 gene of D4V (814669 strain), was previ- 
ously provided by Dr. C.-J. Lai (National Institute of Allergy and 
Infectious  Diseases,  National  Institutes  of Health,  Bethesda, 
MD)  (17, 18). 
Human PBMC.  PBMC from a healthy aduh  who had been 
immunized with a live attenuated experimental D4V vaccine 1 yr 
earlier were collected by leukophoresis and separated by Ficoll- 
Hypaque  density  gradient  centrifugation  (19). PBMC  were 
resuspended in RPMI containing 200/0 FCS and 100/o DMSO, and 
frozen in a programmable cryopreservation chamber (Cryo-Med, 
Mt. Clemens, MI). The HLA type of this donor was A2, A23; 
B35; Cw4; DR7, DK53; DQ2; DPw4. 
Preparation of Dengue Virus Type 4 Antigen.  D4V antigen was 
prepared from infected Vero cell monolayers as previously  described 
(20). Briefly, Vero cell monolayers were infected at a multiplicity 
of infection of 1.0 PFU per cell and incubated at 37~  in MEM 
containing 2% FCS until 50% of the cells displayed cytopathic 
effects. Cells were then harvested by scraping, washed, fixed in 
0.025~  glutaraldehyde in PBS for 15 min on ice, washed again, 
and resuspended at 3  x  10  s cells per ml in RPMI. The suspen- 
sion of fixed cells was then sonicated on ice using a sonic dismem- 
brator (Fisher Chemical Co., Pittsburgh,  PA) and centrifuged at 
1,500g for 10 rain at 4oC. The supernatant was collected, aliquoted, 
and frozen at -70~  Control antigen was prepared similarly from 
uninfected Vero cell monolayers. 
Peptide Synthesis.  Peptides  were synthesized using the RAMPS 
Multiple Peptide Synthesis System (New England Nuclear Prod- 
ucts, Boston, MA), as previously reported (21-23). Some peptides 
were synthesized using the Symphony Peptide Synthesizer (Rainin 
Instruments, Woburn, MA) at the University of  Massachusetts Pep- 
tide Core Facility. Analyses to verify the amino acid composition 
of the peptides and purification of the peptide D4.NS3.500-508 
using HPLC were performed by Dr. Robert Carraway at the Pep- 
tide Core Facility. 
Flow Cytometrl/ Peptide Binding Assay.  A peptide binding assay 
using RMA-S-B*3501 cells was performed as previously described 
(24). Briefly,  RMA-S-B*3501 cells  were cultured at 26~  for 18-24 
h. Cells (6  x  l0  s in 50 #1 of PBS supplemented with 20~  FCS) 
were incubated at 26~  for 1 h with 50/zl of different concentra- 
tions of  peptide solution in 96-well culture plates followed by incu- 
bation at 37~  for 3 h. After washing with PBS containing 20% 
FCS, the cells  were stained with mAb to HLA-Bw6, SFR8-B6 (25), 
and FITC-conjugated  IgG of sheep  anti-mouse Ig antibodies  (Silenus 
Laboratories, Hawthorn, Australia). Fluorescence  intensity was mea- 
sured using a FACScan  | 
Cell Surface Antigen Analysis.  5  x  10  s cells were washed twice 
in ice-cold PBS and stained with FITC-conjugated anti-Leu2 (anti- 
CD8), anti-Leu3 (anti-CD4), or anti-Leu4 (anti-CD3) as previously 
described (26). Control cells were labeled with FITC-conjugated 
normal mouse IgG. Labeled cells were then washed three times 
in ice-cold  PBS. The surface  fluorescence  was quantitated by FACS  | 
analysis (FACS  |  440; Becton Dickinson & Co., Mountain View, 
CA), or the cells were analyzed for CD4 or CD8 expression with 
a fluorescence microscope. 
Stimulation of D4Vimmune PBMC with D4V.  PBMC were sus- 
pended at 5  x  l& cells/m1 in AIM-V medium containing  10% 
heat-inactivated human AB serum (Advanced  Biotechnologies,  Inc., 
Columbia MD). 5  x  l& cells in 1 ml were added to 1.0 ml of 
D4V in 24-well duster plates (Costar Corp.,  Cambridge,  MA), 
as previously  described (27). Viral peptide-specific cytolytic activity 
was assayed using some of these cells after 7 d of culture at 37"C, 
1.0 ml of D4V was then added to the rest of the cells and cytolytic 
activity was assayed again on day 14 at 37~ 
Proliferative Response of PBMC to Viral Peptides.  PBMC (1.5 x 
105 to 2.5  x  105) were cultured with synthetic viral peptides and 
viral antigen  at various dilutions  in 0.2 ml of AIM-V medium 
(GIBCO BILL)  containing 10% human AB serum in 96-well  round- 
bottom microtiter plates (Costar, Corp.) at 37~  for 6 d. The cells 
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vest with a multiharvester (Titertek;  Skatron Inc. Sterling, VA). 
[3H]Thymidine incorporation was counted in a liquid scintillation 
counter (1205 Betaplate; Pharmacia, Wallac Oy, Finland). 
Establishment of Dengue Virus-specific T Cell Clones by Limiting 
Dilution.  PBMC (6  x  106) were "y-irradiated  (3,000 fads) and in- 
cubated for 2 h with peptide D4.NS3.500-508 at 1 #g/rnl in 0.7 
ml of RPMI containing  10% FCS. Cells were then washed five 
times in ILPMI containing  10% FCS, centrifuged together with 
4  x  106 autologous PBMC, and cultured in 48-well plates (Costar 
Corp.) for 7 d in 1 ml of  AIM-V medium supplemented with 10% 
human AB serum. T cell growth factor (T-Stim; Collaborative Re- 
search, Inc., Bedford, MA) was added to the final concentration 
of 10% on day 3. On day 7, 2  x  106 ~,- irradiated autologous 
PBMC were pulsed with peptide D4.NS3.500-508 at 1 #g/m1 for 
2 h and then washed five times. These 3,-irradiated, peptide-pulsed 
PBMC were mixed and centrifuged together with growing cells 
and resuspended in lml of  AIM-V medium containing 10% human 
AB serum and 10% T cell growth factor (TCGF) in 48-well plates. 
The growing cells were restimulated again on days 21 and 35. Half 
of the media in the wells was replaced every 3 d with AIM-V, 15% 
T cell growth factor and 15% human AB serum. 1 wk after the 
last restimulation on day 35, cells were seeded into V-bottom plates 
(Costar Corp.) at concentrations of 100, 10, 3, and 1 cells per well 
with 10  s 3~-irradiated autologous PBMC in 0.2 ml of AIM-V con- 
taining 10% human AB serum, 20 U/ml human rib2 (Collabora- 
tive Research, Inc., Bedford, MA) and 0.1/zg/ml ofmAb to CD3 
(12F6; kindly provided by Dr. Johnson  Wong,  Massachusetts 
General Hospital, Boston, MA). Every 3 d, 0.1 ml of superuatant 
was removed from each well and replaced by AIM-V containing 
10% human AB serum and 20 U/m1 Ib2.2 wk after seeding, half 
of the cells in each well were examined for cytotoxicity against an- 
tologous B lymphoblastoid cell lines (LCL) infected with rVV con- 
taining the D4V NS3 gene (W [D4:NS3]) or with control VV. 
In one limiting dilution experiment, 33 out of 672 wells demon- 
strated cytotoxic activity that was greater than spontaneous release 
+2.56  x  SEM. These ceils were transferred to 48-well plates, and 
were further expanded. The percentages of  the wells that contained 
the growing ceils with specific  cytotoxic activity were 4.9% with 
1 cell per well, 4.2% with 3 cells per well, 8.3% with 10 ceils 
per well, and 43% with 100 cells per well. The nine CTL clones 
used in the experiments were selected based on the specificity and 
growth. Clones 2, 9, 12, and 14 were established from the wells 
that contained 1 cell per well, clones 20, 21, and 22 were estab- 
lished from the wells that contained 3 calls per well, and clone 
26 was established from the well that contained 10 cells per well. 
Pre~ration of Target Cells.  Autologous  LCL  were  derived 
through transformation of peripheralblood lymphocytes with EBV 
as previously described (20) and were maintained in RPMI con- 
taining 10% FCS at 37~  Culture fluid from the EBV transformed 
marmoset cell line, B95-8, was used as a source of EBV. Vaccinia- 
dengue recombinant virus (VV-DV)-infected target cells were pre- 
pared by infecting 106 LCL with VV-DV at a multiplicity of in- 
fection of ~20 PFU per cell for 2 h. After being washed twice, 
LCL were cultured  in RPMI containing  10% FCS at 37~  for 
16-20 h and were used as target ceils. 
D2V-infccted LCL were established by infection of 4  x  10  s 
LCL with 0.25 ml of an undiluted supernatant from D2V-infected 
Raji cells and were maintained in cultures for 2-6 wk before use 
as CTL targets. 50-70% of the D2V-infected  LCL contained dengue 
virus antigen as detected by immunofluoresceuce using hyperim- 
mune anti-D2V  mouse ascites fluid 2 and 4 wk after infection. 
Target cells were washed twice in RPMI containing 10% FCS 
and were labeled by incubation with 0.25 mCi Na251CrO4 (New 
England Nuclear Research Products, Boston, MA) for 45-60 rain 
in 0.1 ml at 37~  After four washes to remove excess SlCr, target 
cells were counted and resuspended at 104 cells per ml for use in 
cytotoxicity assays. 
SICr Release Cytotoxicity Assay.  Cytotoxicity assays were per- 
formed in 96-well round-bottom plates as previously reported (22, 
26). Effector ceils in 0.1 ml of RPMI containing  10% FCS were 
added to 1 x  103 SlCr-labeled target cells in 0.1 ml at E/T ratios 
of 50-100:1 for bulk cultures and 5-10:1 for CTL clones. In cyto- 
toxicity assays using synthetic peptides, 0.05 ml of synthetic pep- 
tides was added to 103 target ceils in 0.1 ml, incubated at 37~ 
for 30 min, and 0.05 ml of  effector calls were then added. All assays 
were performed in triplicate. After centrifugation  at 200 g for 5 
min, plates were incubated at 37~  for 4-5 h. Supernatant fluids 
were harvested and the SICr content was measured in a gamma 
counter (Packard  Instrument s, Sterling, CA). The percent of  specific 
release was calculated using  the formula: 
[(cpm experimental release) -  (cpm spontaneous release)] x  100 
[(cpm maximal release) -  (cpm spontaneous release)]. 
Results 
Proliferative Responses of Donor 1 PBMC to the Synthetic Viral 
Peptide D4.NS3.500-508 and Recognition of the Peptide by CTLs 
Generated in Bulk Cultum  We have previously reported that 
the epitopes that are recognized  by dengue virus-specific, HLA- 
B35-restricted CD8 + CTL clones established by stimulation 
with D4V are located within amino acids 453-618 of NS3 
(14).  The motif for HLA-B35-binding peptides  has been 
reported to be nine-amino acids peptides that contain a pro- 
line at the second position (28). Eight nine-amino acid pep- 
tides were prepared based on the HLA B35-binding motif 
from the amino acid sequence located between amino acids 
453 and 618  of D4V  NS3. 
PBMC from this D4V-immune, HLA-B35-positive donor 
were cultured with each of these peptides and T cell prolifer- 
ation was examined. PBMC proliferated when cultured with 
peptide D4.NS3.500-508  (TPEGIItrrL), but did not pro- 
liferate when cultured with  the other peptides (Table 1). 
D4. NS3.500-508 did not induce proliferation of  PBMC from 
a dengue virus-non immune, HLA-B35-positive donor or 
cord blood lymphocytes (data not presented). 
We then examined whether D4.NS3.500-508 is recognized 
by CTLs generated by stimulation with DV4 in bulk culture 
(Table 2).  PBMC from the D4V-immune donor were cul- 
tured with D4V for 7 d  (Experiment 1), and further cul- 
tured with D4V for seven more days in the presence of 10% 
TCGF (Experiment 2). Lysis of autologous LCL that had been 
pulsed with each of the eight peptides by CTL generated 
in bulk cultures was examined. CTLs generated by stimula- 
tion with D4V in bulk cultures lysed target cells pulsed with 
D4.NS3.500-508, but did not lyse target cells pulsed with 
the other peptides. These results suggest that D4.NS3.500- 
508 is the only HLA-B35-restricted epitope recognized by 
D4V-specific CTLs between amino acids 453 and 618 on NS3. 
We quantified the binding of these peptides to HLA-B*3501 
molecules by flow cytometry analysis of RMA-S cells trans- 
fected with the HLA-B*3501 gene as described in Materials 
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Dengue Peptides* 
Table 2.  Recognition  of D4.NS3.509508 by CTLs Generated 
in Bulk Culture with D4V* 
Stimulation index* 
Peptide 
concentrations 
Amino acid 
Peptides  sequences  1  0.1  0.01 
/zg/ml 
D4.NS3.464-472  NPAQEDDQY  0.7  1.0  ND 
D4.NS3.477-485  DPLKNDEDH  0.8  1.1  ND 
D4.NS3.500-508  TPEGII PTL  2.__fi6  2.__77  1.8 
D4.NS3.505-513  IPTLFGPER  0.9  0.8  ND 
D4.NS3.510-518  GPEREKTQA  1.0  1.1  1.0 
D4.NS3.542-550  LPVWLSYKV  1.2  1.1  ND 
D4.NS3.592-600  RPRWLDARV  1.7  1.1  ND 
D4.NS3.603-611  DPMALKDFK  1.3  0.8  ND 
D4 AgS  10.7 
Control  Ag  1.1 
* PBMC (2 x  10  s cells) were incubated for 7 d in the presence of pep- 
tides, dengue virus, or control antigen. 10% TCGF was added on day 
3.  Cells were pulsed with 1.5 #Ci of [3H]thymidine  for 10 h, and 
[3H]thymidine  incorporation  was measured. Stimulation  indices  of >t2.0 
are underlined. 
Stimulation  index is the ratio of [3H]thymidine  incorporation (cpm) in 
the presence of peptides or antigens to [3H]thymidine  incorporation 
(cpm) in the absence of antigens. [3H]thymidine  incorporation  without 
antigen was 14,970 cpm. 
S  D4V antigen  was prepared as described in Materials and Methods  and 
used at a 1:120 dilution. 
and Methods (Table 3). Six of the eight peptides, including 
peptide D4.NS3.500-508,  bound to HLA-B*3501, while two 
peptides did not bind. The results shown in Tables 1-3 sug- 
gest that the stimulation of the PBMC by D4.NS3.500-508 
is caused, not only by the peptide's ability to bind to HLA- 
B35, but also by specific recognition of this peptide by CTLs. 
Recognition of Dengue Virus NS3 Protein and the Peptide 
D4.NS3.500-508  by  Dengue Virus-specific CD8 +  CTL 
Clones.  The PBMC from this D4V-immune donor were cul- 
tured with peptide D4.NS3.500-508 for 6 wk and was then 
subjected to limiting dilution to isolate CTL clones as de- 
scribed in Materials and Methods. Those CTL clones, which 
demonstrated D4V NS3-specific cytotoxicity  in the screening 
CTL assays, were expanded and nine clones were selected. 
These nine CTL clones had a CD3 + CD4-  CD8 + pheno- 
type, as determined by immunofluorescence staining. 
After establishment, each of the nine CD8 + CTL clones 
was again examined for cytotoxicity against VV[D4:NS3]- 
infected and Ix'pride D4.NS3.500-508-pulsed  autologous LCL. 
All the tested CTL clones lysed VV[D4:NS3]-infected and 
peptide D4.NS3.500-508-pulsed target cells (Table 4). Rec- 
ognition of two eight-amino acid peptides, D4.NS3.501- 
Autologous LCL 
infected or 
pulsed with 
Percent of specific SlCr release* 
Experiment 1  Experiment  2 
VV [D4:NS3]S  56  47 
VV [control]  4  3 
D4.NS3.464-472  0  0 
D4.NS3.477-485  ND  0 
D4.NS3.500-508  80  86 
D4.NS3.505-513  ND  0 
D4.NS3.510-518  ND  0 
D4.NS3.542-550  ND  0 
D4.NS3.592-600  ND  0 
D4.NS3.603-611  0  0 
None  0  ND 
*  103 autologous  LCL target cells were incubated  with effector  cells in 
the presence of peptides at 0.025/zg/ml for 5 h. 
Effectors were generated in 7-d bulk culture (Experiment 1) and 14-d 
bulk culture (Experiment 2). E/T cell ratios were 100:1 and 50:1 in Ex- 
periments 1 and 2, respectively. 
S  VV [D4:NS3] indicates recombinant vaccinia virus that contains the 
gene coding for the NS3 protein of D4V. 
508  and  D4.NS3.500-507,  which  are  NH2-terminal  and 
COOH-terminal mmcations of  D4.NS3.500-508,  respectively, 
was then examined. These two peptides were not recognized 
or  were  recognized  to  much  lower  levels  compared  to 
D4.NS3.500-508 by peptide-induced, dengue virus-specific 
CD8 + CTL clones (data not presented).  This result indicates 
that the nine-amino acid peptide D4.NS3.500-508 represents 
the smallest  recognition unit. 
Lysis of Dengue Virus-infected Autologous LCL  by CD8 + 
CTL Clones.  To confirm that the CD8 + CTL clones es- 
tablished by stimulation with the peptide D4.NS3.500-508 
lyse dengue virus-infected target cells, we examined the ability 
of the CTL clones 12 and 20-22 to lyse autologous LCL in- 
fected with D2V. These CTL clones lysed D2V-infected au- 
tologous LCL, but did not lyse uninfected LCL (Table 5). 
Dengue Virus Serotype Specificities of CD8 + CD4-  CTL 
Clones.  To determine dengue serotype specificities of the 
CD8 + CTL clones, we examined cytotoxicity against autol- 
ogous LCL infected with VV [D2:NS3], VV [D3:NS3], or 
VV [D4:NS3]  (Table 6).  CTL clones 9 and 14 lysed target 
calls infected with VV [D4:NS3], but did not lyse target cells 
infected with other recombinant VV. Clone 12 lysed target 
cells infected with VV [D2:NS3] and VV [D4:NS3] and clones 
2, 17, and 26 lysed target cells infected with VV [D3:NS3] 
and VV [D4:NS3]. Clones 20-22 lysed target cells inf~ted 
with any of the three VV constructs. These results indicate 
that  CD8 +  T  cell  clones with  four  distinct  patterns  of 
dengue serotype specificities were established by stimulation 
856  Peptide-stimulated  Cytotoxic  T Lymphocyte  Clones Table 3.  Quantitation of the Binding of Eight Peptides Synthesized  from the Amino Acid Sequence of D4V NS3 to 
HLA-B*3501  Molecules* 
Mean fluorescence intensity 
Concentration of peptides (pM) 
Experiment  Peptide  1,000  800  400  200  100  10  1  0.1  0.01 
1  D4.NS3.477-485  143  84  63  48  40  40  37  36 
D4.NS3.500-508  219  197  194  180  82  46  40  37 
D4.NS3-505-513  140  97  55  36  38  42  41  38 
D4.NS3.542~  156  144  97  53  41  40  40  38 
D4.NS3.592-600  24  36  41  45  45  47  41  41 
D4.NS3.603-611  208  191  142  77  45  41  38  37 
2  D4.NS3.464-472  118  51  45  41  41 
D4.NS3.500-508  193  93  57  48  48 
3  D4.NS3.510-518  47  46  45  52  47  48 
DR.NS3.500-508  327  210  113  60  49  49 
* Peptide binding assays were performed using RMA-S-B*3501 cells as described in Materials and Methods. Mean fluorescence intensities without 
peptide were 37 in Experiment  1, 44 in Experiment 2, and 48 in Experiment 3. 
The - symbol indicates concentrations not tested. 
with a single viral peptide. The bulk-cuhured T  cell line that 
had been stimulated with D4.NS3.500-508  for 6  wk lysed 
target  cells infected with  VV[D2:NS3],  VV[D3:NS3],  or 
VV[D4:NS3]. 
We  then  synthesized  peptides  D2.NS3.500-508  (TPE- 
GIIPSM) and D3.NS3.500-508  (TPEGIIPAL), which cor- 
respond to amino acids 500-508 of dengue 2 NS3 and dengue 
3  NS3 respectively, to examine serotype specificities of the 
T  cell clones at the peptide levels. The patterns of dengue 
virus serotype specificities determined using VV were con- 
Table 4.  Recognition of Peptide D4.NS3.SOO-SO8-pulsed  and VV[D4:NS3]-infected Autologous Target Cells by Dengue Virus-specific 
CD8 +  T  Cell Clones* 
Percent of Specific SlCr  release 
Dengue-  Peptide D4.NS3.500-508  (pg/ml)  Control peptide (/~g/ml)* 
specific  No 
clones  2.5  2.5  x  10 -2  2.5  x  10 -4  2.5  x  10 -6  2.5  2.5  x  10 -2  peptide  VV  [D4:NS3]S 
2  85  87  55  0  0  0  0  68 
9  56  49  12  0  0  0  0  35 
12  37  40  2  0  0  0  0  33 
14  79  71  44  0  0  0  0  66 
17  70  63  57  0  1  0  0  31 
20  90  89  72  0  0  0  1  87 
21  79  71  38  0  0  0  0  50 
22  26  36  11  0  0  0  1  18 
26  60  62  37  0  1  0  1  30 
* A total of 103 autologous target cells were incubated with effector cells 
* D4.NS3.464-472  was used as a control peptide. 
s VV  [D4:NS3] depicts rVV that contains genes coding for NS3 protein 
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in the presence or absence of peptides for 5 h. E/T cell ratio was 10:1. 
of D4V. Table 5.  Lysis of Autologous LCL Infected with D2Vs by 
CD8 + CTL  Clones* 
Percent  of specific 51Cr release 
CD8 § CTL  clones  D2V-infected  Uninfected 
12  30  0 
20  59  6 
21  67  0 
22  34  0 
* 103 target cells were incubated with effector cells for 4 h. D2V-infected 
and uninfected  autologous LCL were used as target cells. E/T ratio was 
10:1. 
sistent with the serotype specificities  determined at the pep- 
tide level (Table 7). The published sequence of amino acids 
500-508 on NS3 is completely conserved between D3V and 
D1V viruses (29, 30). Therefore, we assume that  the CTL 
clones  that  recognized  D3V  NS3  would  also  recognize 
D1V NS3. 
HLA-B35 Restriction of Dengue  Virus-specific CD8 + CTL 
Clones.  HLA restriction of the lysis of target cells by the 
CD8 + T  cell clones was examined using a panel of HLA- 
typed allogeneic LCL (Table 8). Seven CTL clones were tested, 
and they all lysed peptide D4.NS3.500-508-pulsed aUogeneic 
LCL that shared HLA-B35, but they did not lyse D4.NS3.500- 
508-pulsed LCL that  did not share HLA-B35. To confirm 
that our clones are HLA-B35 restricted, we also used a mu- 
rine P815 cell line transfected with the HLA-B*3501 gene. 
Three clones, 14, 20, and 21, were tested and they lysed P815- 
B35 cells pulsed with peptide D4.NS3.500-508, but did not 
lyse P815-B35 cells pulsed with peptide D4.NS3.464-472 or 
cells not pulsed with any peptides (data not presented). These 
results indicate that  the CD8 + T  cell clones are HLA-B35 
restricted. 
Recognition of the Peptides with Amino Acid Substitution  by 
Dengue  Virus-specific  CD8 + CTL  Clones.  To  define  the 
differences in the recognition  of the peptide D4.NS3.500- 
508 by CD8 + CTL dones of different serotype specificities, 
we examined the effect of amino acid substitutions at single 
positions  on  recognition.  Nine  peptides  that  have  aspar- 
tic  acid  (D)  at  one  of the  nine  amino  acid  positions  of 
D4.NS3.500-508 were synthesized.  Three of the nine pep- 
tides, those that had D  at the 2nd, 6th, or 7th position, did 
not bind to HLA-B*3501, but the other six substituted pep- 
tides bound (Table  9). 
We examined these six substituted peptides (D4.NS3.500- 
500D,  502D,  503D,  504D,  507D,  and 508D) that  showed 
significant binding to HLA-B*3501 for recognition by CD8 + 
CTL clones in cytotoxicity assays (Table 10). The D4V specific 
Table  6.  Dengue  Serotype Specificities of Dengue  Virus-specific CD8 § CTL  Clones* 
Dengue-specific clones 
Percent  of specific SlCr release 
VV  [D2:NS3]  VV  [D3:NS3]  VV  [D4:NS3]*  VV  [control] 
Bulk cultures  44  81  69  5 
Serotype-specific 
9  2  0  60  3 
14  0  1  61  0 
Subcomp~x specific 
12  62  1  38  1 
2  18  90  65  8 
17  3  66  52  1 
26  7  67  54  0 
Serotype cross-reactive 
20  60  79  35  0 
21  71  81  39  0 
22  48  65  30  0 
* 103 target cells were incubated  with effector cells for 5 h.  The E/T ratios  were 8:1 for clone 20,  and  10:1 for clones 2,  9,  12,  14,  17, 21,  22, 
and  26.  The E/T ratio was  50:1 for bulk culture. 
VV [D2:NS3], VV [D3:NS3], and VV [D4:NS3]  depict  recombinant vaccinia viruses that contain genes coding for NS3 protein of D2V, D3V, 
and D4V,  respectively. 
S PBMC were stimulated  with the peptide D4.NS3.500-508  in bulk culture for 6 wk. 
858  Peptide-stimulated  Cytotoxic T  Lymphocyte  Clones Table 7.  Serotype Specificities of Dengue  Virus-specific CD8 + CD4-  CTL  Clones at the Peptide Levels" 
Percent of specific StCr release of autologous targets with peptide# 
D2.NS3.500-508  (/zg/ml)  D3.NS3.500-508  (/zg/ml)  D4.NS3.500-508  (/~g/ml) 
Dengue-specific clones  2.5  2.5  x  10 -z  2.5  2.5  x  10 -z  2.5  2.5  x  10 -z 
Serotype specific 
9  0  0  2  0  61  35 
14  0  0  0  0  76  60 
Subcomplex specific 
12  23  0  1  0  52  69 
2  20  1  57  11  90  85 
17  0  0  23  6  69  73 
Serotype cross-reactive 
20  68  66  78  64  84  88 
21  71  69  59  46  66  63 
* 103 autologous LCL target cells were incubated with effector cells in the presence of peptides at different concentrations (2.5 #g/ml, 2.5  x  10 -2 
/~g/ml) for 5 h. E/T cell ratios were 10:1 percent specific SlCr release without peptide was 0% for clone 9, 0% for clone 14, 1% for done 12, 
0% of clone 2, 0% for clone 17, 0% for clone 20, and 0% for clone 21. 
* Sequences of NS3:500-508 are TPEGIIPSL for D2V, TPEGIIPAL for D3V, and TPEGIIPTL for D4V. 
clones 9 and 14 did not recognize peptides 503D, 504D, 507D, 
or 508D.  The subcomplex-specific clones 12, 2, and 17 did 
not recognize 500D, 503D, or 507D, while the serotylx"-cross- 
reactive clones 20 and 21 did not recognize 503D. These results 
suggest that all of the CD8 + CTL clones of different sero- 
type specificities recognize the original peptide D4.NS3.500- 
508, but the manner of recognition by these CTL clones is 
different, depending on serotype specificities of the clones. 
Discussion 
In this paper we characterized dengue virus-specific CD8 § 
CTL  clones  established  by  stimulation  with  the  peptide 
Table 8.  Determination of HLA  Class I  Restriction of CD8 + CTL 
D4.NS3.500-508.  The  peptide-stimulated,  dengue  virus- 
specific human CD8 +  CD4-  T  cell clones were heteroge- 
neous with a  minimum  of four patterns  of serotype spec- 
ificities:  (a) D4V-specific;  (b) cross-reactive for D1V,  D3V, 
and D4V; (c) cross-reactive for D2V and D4V; and (d) cross- 
reactive for all four dengue virus serotypes. The serotype-cross- 
reactive clones 20, 21, and 22 were established from the wells 
that contained three cells per well; however, only 4% of the 
wells that originally contained three cells per well had the 
growing cells with specific cytotoxic activity. Analysis of TCR 
V  gene usage by the previously reported PCR method (31) 
revealed that dones 20, 21, and 22 used a single TCR V gene, 
Vow8 and V/35.2.  These results  strongly suggest that  these 
Clones Using Peptide-pulsed Allogeneic  Target  Cells* 
HLA class I  type~  Percent of specific SiCr release 
Target  A  B  C  2  9  12  14  17  20  21 
Autologous  2/23  35/44  w4  88  84  39  84  65  85  58 
JC  3/24  35  w__44  80  87  35  84  86  84  55 
TG  23/29  7/44  w_44  6  7  0  3  4  16  6 
M  24/30  13/55  w__44/w6  6  11  0  3  1  24  5 
VA  12  1/24  35  w__44  85  37  19  20  28  68  26 
VA 03  2/24  7/35  w3/w7  73  50  17  38  34  55  29 
* A total of 103 targets were incubated with effector cells in the presence of peptide D4.NS3.500-508 (TPEGIIPTL) at 2.5  x  10 -2 /~g/ml for 
5 h.  The E/T cellratio was  10:1  for clones 2,  9,  14,  20,  21,  and  22,  and 8:1 for clones  12 and  17. 
* HLA loci that match donor HLA are underlined. 
859  Zivny et al. Table 9.  Quantitation  of the Binding  of Araino Acid Substituted D4.NS3.500-508  Peptides to HLA-B'3501  Molecules* 
Mean fluorescence intensity 
Concentration  of peptides (#M) 
Amino acid 
Peptides  b  sequences  1,000  100  10  1  0.1  0.01 
D4.NS3.500-508  TPEGIIPTL  316  253  125  74  76  64 
D4.NS3.500.500 
D  DPEGIIPTL  311  190  88  70  65  67 
D4.NS3.500.501 
D  TDEGIIPTL  74  72  74  71  66  71 
D4.NS3.500.502 
D  TPDGIIPTL  266  125  74  69  71  69 
D4.NS3.500.503 
D  TPED__IIPTL  373  301  177  100  73  71 
D4.NS3.500.504 
D  TPEGDIPTL  273  147  78  70  67  63 
D4.NS3.500.505 
D  TPEGI__DPTL  70  62  69  64  71  71 
D4.NS3.500.506 
D  TPEGIID__TL  83  73  65  67  70  71 
D4.NS3.500.507 
D  TPEGIIPDL  328  202  71  69  72  62 
D4.NS3.500.508 
D  TPEGIIPTD  134  66  64  66  65  69 
* Peptide binding assays  were performed  using RMA-S-B*3501 cells as described in Materials and Methods. The mean fluorescence  intensity  in the 
absence of peptide was 69. Peptides tested  included a series of peptides with aspartic acid substitutions  indicated  by the underlined  D in the sequence. 
dories represent individual clones with broad reactivity rather 
than mixture of the clones.  Furthermore, there were clones 
2 and 10 that were established from the wells that originally 
contained one cell per well, and that had the same serotype 
cross-reactivity as clones 20-22. Unfortunately, clones 2 and 
10 did not grow enough to be used throughout the entire 
experiments (data not presented). 
Serotype specifidties determined using a rVV were consis- 
tent with those determined using synthetic peptides. We used 
dengue-vaccinia recombinant viruses that contained genes for 
the NS3 of D2V, D3V,  or D4V,  and the peptides that cor- 
responded  to  amino  acids  500-508  on  NS3  proteins 
of D2V,  D3V,  and  D4V.  Peptides  D2.NS3.500-508  and 
D3.NS3.500-508  have some amino acid substitutions as com- 
pared to the D4V peptide. Peptide D2.NS3.500-508 has two 
amino acid substitutions; S for T  at amino acid 507 and M 
for L at amino acid 508  (32,  33).  D1V and D3V have the 
same amino acids sequences at amino acids 500-508,  and have 
one amino acid substitution as compared to D4V; A for T 
at amino acid 507 (29, 30, 32). CTLs cross-reactive for D4V 
and D2V recognized peptides D2.NS3.500-508,  and those 
cross-reactive for D4V and D3V recognized D3.NS3.500-508. 
The serotype specificities of CD8 § CTL clones are deter- 
mined by the interaction of the TCR with peptides that are 
bound to HLA. The amino acids at the 2nd and 9th posi- 
tions of the peptide are reported to be residues that are im- 
portant for binding to HLA-B35 (24). Amino acids 500-506 
are  completely conserved among D1V-D4V.  Thus,  if we 
hypothesize that TCR of CTL clones of heterogeneous sero- 
type specificities recognize the amino acids at the same posi- 
tion of the peptide as critical residues,  amino acid 507 may 
be critical for recognition by these CTL clones. The results 
suggest that the TCRs of dengue 4-specific and subcomplex- 
specific CTL clones may be very specific and distinguish the 
difference of amino acids between D4V and other serotypes 
of dengue viruses,  whereas the TCRs of CTL clones 20-22 
do not discriminate this difference. Alternatively, TCRs of 
serotype--cross-reactive  CTL  clones  20-22  may recognize 
between amino acids 500 and 506 which are completely con- 
served among the four dengue serotypes, as the critical residues. 
The other possibility is that the critical residues for TCR 
binding are the same for all of the CTL clones and are con- 
served among four serotypes of dengue viruses,  but are ex- 
posed differently  on HLA-B35 (34). For example, the binding 
860  Peptide-stimulated  Cytotoxic  T Lymphocyte  Clones Table  10.  Recognition of Amino Acid Substituted D4.NS3.500-508 Peptides by Dengue Virus-specific CD8 + CTL Clones" 
Percent  relative lysis compared  to D4.NS3.500-508 
Dengue-specific clones  500*  502D  503D  504D  507D  508D 
Serotypespecific 
9  67  70  9  9  2  36 
14  87  87  4  17  0  20 
Subcomplex  specific 
12  45  121  12  97  0  112 
2  23  107  20  91  0  70 
17  8  72  25  64  1  83 
Serotype cross-reactive 
20  23  94  9  76  47  94 
21  63  75  13  46  100  90 
* Percent of relative lysis compared to D4.NS3.500-508 was calculated by the formula: 100 x  (percent of specific slCr release with or substituted 
peptide at 25 #g/ml)/(percent of specific 51Cr release with D4.NS3.500-508 at 25/zg/ml).  Percent of specific stCr release with D4.NS3.500-508 
was: 74% (clone 2), 69% (clone 9), 33% (clone 12), 77% (clone 14), 36% (clone 17), 87% (done 20), and 24% (done 21) for 500D, 502D, 503D 
and 504D; and 91% (done 2), 76% (done 9), 76% (clone 12), 60% (clone 14), 88% (done 17), 80% (done 20), and 78% (done 21) for 507D and 508D. 
+  The  amino acid sequences of  the  substituted  peptides were 500D, D__PEGIIPTL; 502D, TPDGIIPTL; 503D, TPEDIIPTL;  504D, 
TPEG__DIPTL; 507D, TPEGIIP__DL; 508D, TPEGIIPTD. 
of D3.NS3.500-508 to HLA-B35 may be different from that 
of D4.NS3.500-508 because of the substitution of the amino 
acid at the 8th position.  It is possible that  serotype-cross- 
reactive CTL clones recognize the critical residues on both 
of the peptides bound to HLA-B35, while D4V-specific CTL 
clones can recognize the critical residues on D4.NS3.500-508, 
but cannot recognize the same critical residues on D3.NS3.500- 
508 bound to HLA-B35. 
To further understand the interaction of TCRs with crit- 
ical amino add residues of the peptide, we prepared nine ix,  prides 
by  substituting  each  of  the  nine  amino  acids  of  the 
D4.NS3.500-508 with aspartic acid. The recognition of these 
substitutions by the CD8 + CTL clones varied depending on 
the serotype specificities  of the clones. The peptide D4.NS3. 
500.503D, which has an aspartic acid substitution at the 4th 
position, was not recognized by any of the clones, although 
this peptide bound to HLA-B35, as well as the original pep- 
tide D4.NS3.500-508.  The peptide D4.NS3.500.504D was 
not recognized by the D4V-specific  CTL clones, but was rec- 
ognized by the subcomplex-specific and serotype-cross-reactive 
CTL clones. The peptide D4.NS3.500.507D was not recog- 
nized by the D4V-specific or subcomplex-specific CTL clones, 
but was recognized by the serotype-cross-reactive  clones. These 
results are consistent with the reports that the TCR has con- 
tact with more than one amino acid residue of an antigenic 
peptide bound to the HLA (35, 36), and that glutamic acid 
at the 4th position, which is conserved among the four sero- 
types of dengue viruses, may be the most critical residue for 
861  Zivny et al. 
recognition.  These results also suggest that  the differences 
in the recognition of the D2V, D3V, and D4V peptides may 
be caused by the differences in the configuration of these pep- 
tides when they are bound to HLA. On the other hand, rec- 
ognition  of D4.NS3.500.507D  by  serotype-cross-reactive 
clones, but not by D4V-s or subcomplex-specific clones, sug- 
gest that the critical residue for recognition may be different 
among T calls of different serotype specificities.  Further ex- 
periments are necessary to ddineate the interactions  of the 
TCR of these CTL clones and dengue peptides. 
Dengue virus infections are a serious cause of human mor- 
bidity and mortality in tropical and subtropical areas of the 
world (37, 38). The pathological mechanisms, which result 
in  a severe complication  of some dengue virus infections, 
termed dengue hemorrhagic fever (DHF), are not understood. 
Patients with DHF are usually undergoing the secondary in- 
fection with a different serotype of dengue virus than  that 
which caused the primary infection (39). Patients with DHF 
have  highly activated CD8 + and CD4 § T  cells  (40).  The 
presence of activated CD8 + CTL during a secondary dengue 
virus infection raises the possibility that these CTL may con- 
tribute  to the pathogenesis  of DHF through  lymphokine 
production and lysis of dengue virus-infected monocytes. On 
the other hand, a strong dengue virus-specific CTL response 
is probably necessary for recovery from dengue virus infec- 
tion. Currently, there is no effective vaccine against dengue 
virus infections, although live attenuated experimental vac- 
cines that induce immune responses in humans have been de- veloped (41, 42).  Putative vaccine(s)  should induce strong 
protective immune responses, but should not lead to the patho- 
genesis  of DHF.  Definition of the epitopes recognized by 
dengue virus-specific  CD8 + CTL provides information that 
is useful for the development of safe and effective vaccines. 
We have shown that a single nine-amino acid peptide in- 
duced  virus-specific  CTLs  with  heterogeneous  serotype 
specificities from PBMC of a dengue virus-immune donor. 
The priming with live attenauted virus in vivo, however, may 
have had a profound effect on the precursor pool of CTL, 
and primary vaccination with the nine-amino acid peptide 
may give significantly different results. Synthetic peptides have 
not yet been successfully developed as human vaccines. The 
strategy presented in this paper addresses virus heterogeneity 
of CTLs induced by a single peptide, but is still subject to 
the constraints of HLA heterogeneity. Therefore, immuni- 
zation with a subunit vaccine containing a single T cell epi- 
tope is not a realistic approach to inducing broad immunity 
in an outbred population. 
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